S2303

This study is for patients who have progressed on standard of care treatment for gastric or esophageal cancer. The study looks at adding Nivolumab to 2nd line treatment to see if it improves outcomes.
Contact phone
(517) 364-2910
Contact email
cancerclinicaltrials@sparrow.org
Principal investigator
Dr. Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Gastric or Esophageal
Webform